Nifty
Sensex
:
:
10821.85
35689.60
80.75 (0.75%)
257.21 (0.73%)

Pharmaceuticals & Drugs

Rating :
44/99

BSE: 500124 | NSE: DRREDDY

2336.25
19.85 (0.86%)
22-Jun-2018 | 3:53PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  2325.00
  •  2347.50
  •  2274.05
  •  2316.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1667277
  •  38951.76
  •  2787.00
  •  1887.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 38,753.92
  • 40.93
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 43,285.92
  • 0.86%
  • 3.08

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 26.76%
  • 17.03%
  • 8.73%
  • FII
  • DII
  • Others
  • 0.23%
  • 14.50%
  • 32.75%

Chart

Price | P:E | P:BV | EV:EBITDA

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Var%
Dec 17
Dec 16
Var%
Sep 17
Sep 16
Var%
Jun 17
Jun 16
Var%
Net Sales
3,553.90
3,611.90
-1.61%
3,834.10
3,723.20
2.98%
3,559.80
3,616.30
-1.56%
3,333.20
3,222.50
3.44%
Expenses
2,990.30
3,021.40
-1.03%
3,041.40
2,858.70
6.39%
2,890.40
2,989.30
-3.31%
3,010.00
2,832.30
6.27%
EBITDA
563.60
590.50
-4.56%
792.70
864.50
-8.31%
669.40
627.00
6.76%
323.20
390.20
-17.17%
EBIDTM
15.86%
16.35%
20.68%
23.22%
18.80%
17.34%
9.70%
12.11%
Other Income
44.90
20.50
119.02%
43.00
40.30
6.70%
31.60
43.80
-27.85%
38.00
67.00
-43.28%
Interest
17.80
19.60
-9.18%
17.20
16.40
4.88%
22.30
12.60
76.98%
21.50
14.80
45.27%
Depreciation
276.30
254.30
8.65%
271.50
266.50
1.88%
270.20
262.20
3.05%
259.20
243.60
6.40%
PBT
314.40
337.10
-6.73%
547.00
621.90
-12.04%
408.50
396.00
3.16%
80.50
198.80
-59.51%
Tax
49.20
9.70
407.22%
252.80
138.50
82.53%
112.30
95.60
17.47%
23.70
52.60
-54.94%
PAT
265.20
327.40
-19.00%
294.20
483.40
-39.14%
296.20
300.40
-1.40%
56.80
146.20
-61.15%
PATM
7.46%
9.06%
7.67%
12.98%
8.32%
8.31%
1.70%
4.54%
EPS
16.39
20.36
-19.50%
18.26
29.69
-38.50%
18.42
18.63
-1.13%
4.02
9.27
-56.63%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Net Sales
14,281.00
14,196.10
15,568.30
15,023.30
13,415.30
11,895.60
9,814.50
7,496.90
6,988.60
6,900.60
4,991.80
Net Sales Growth
0.76%
-8.81%
3.63%
11.99%
12.78%
21.20%
30.91%
7.27%
1.28%
38.24%
 
Cost Of Goods Sold
4,039.50
3,444.90
3,758.50
3,786.40
3,317.10
3,516.80
2,568.30
2,091.10
2,061.70
1,940.40
1,601.20
Gross Profit
10,241.50
10,751.20
11,809.80
11,236.90
10,098.20
8,378.80
7,246.20
5,405.80
4,926.90
4,960.20
3,390.60
GP Margin
71.71%
75.73%
75.86%
74.80%
75.27%
70.44%
73.83%
72.11%
70.50%
71.88%
67.92%
Total Expenditure
11,932.10
11,723.90
11,983.00
11,529.70
10,164.70
9,176.10
7,374.90
5,936.00
5,563.50
5,587.60
4,155.10
Power & Fuel Cost
-
330.10
315.20
339.10
319.90
335.40
225.90
183.30
141.50
122.70
97.60
% Of Sales
-
2.33%
2.02%
2.26%
2.38%
2.82%
2.30%
2.45%
2.02%
1.78%
1.96%
Employee Cost
-
3,106.80
3,117.40
2,944.60
2,475.40
1,928.70
1,591.20
1,304.80
1,183.20
992.00
731.00
% Of Sales
-
21.88%
20.02%
19.60%
18.45%
16.21%
16.21%
17.40%
16.93%
14.38%
14.64%
Manufacturing Exp.
-
2,138.20
1,856.40
1,999.10
1,747.60
1,441.30
1,237.00
985.90
921.80
1,115.30
768.40
% Of Sales
-
15.06%
11.92%
13.31%
13.03%
12.12%
12.60%
13.15%
13.19%
16.16%
15.39%
General & Admin Exp.
-
1,339.90
1,271.40
1,037.30
1,004.30
796.30
682.90
479.00
413.50
582.30
395.80
% Of Sales
-
9.44%
8.17%
6.90%
7.49%
6.69%
6.96%
6.39%
5.92%
8.44%
7.93%
Selling & Distn. Exp.
-
1,293.40
1,181.10
1,357.50
1,264.80
1,119.10
984.40
744.90
691.00
651.30
523.30
% Of Sales
-
9.11%
7.59%
9.04%
9.43%
9.41%
10.03%
9.94%
9.89%
9.44%
10.48%
Miscellaneous Exp.
-
70.60
483.00
65.70
35.60
38.50
85.20
147.00
150.80
183.60
523.30
% Of Sales
-
0.50%
3.10%
0.44%
0.27%
0.32%
0.87%
1.96%
2.16%
2.66%
0.76%
EBITDA
2,348.90
2,472.20
3,585.30
3,493.60
3,250.60
2,719.50
2,439.60
1,560.90
1,425.10
1,313.00
836.70
EBITDA Margin
16.45%
17.41%
23.03%
23.25%
24.23%
22.86%
24.86%
20.82%
20.39%
19.03%
16.76%
Other Income
157.50
171.50
295.00
274.10
169.90
149.90
132.30
52.30
103.10
99.40
214.10
Interest
78.80
63.40
82.60
108.20
126.70
100.30
114.10
32.30
38.50
108.20
102.20
Depreciation
1,077.20
1,026.60
938.90
759.90
647.50
550.20
518.10
398.10
413.10
497.70
401.90
PBT
1,350.40
1,553.70
2,858.80
2,899.60
2,646.30
2,218.90
1,939.70
1,182.80
1,076.60
806.50
546.70
Tax
438.00
296.50
751.10
563.20
683.10
637.90
503.50
183.90
266.80
260.80
107.70
Tax Rate
32.43%
19.08%
26.27%
19.42%
25.81%
29.47%
27.90%
15.55%
43.15%
-39.74%
19.70%
PAT
912.40
1,257.20
2,107.70
2,336.40
1,963.20
1,526.80
1,300.90
998.90
351.50
-917.10
439.80
PAT before Minority Interest
912.40
1,257.20
2,107.70
2,336.40
1,963.20
1,526.80
1,300.90
998.90
351.50
-917.10
439.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.80
PAT Margin
6.39%
8.86%
13.54%
15.55%
14.63%
12.83%
13.25%
13.32%
5.03%
-13.29%
8.81%
PAT Growth
-27.44%
-40.35%
-9.79%
19.01%
28.58%
17.36%
30.23%
184.18%
138.33%
-308.53%
 
Unadjusted EPS
57.09
77.53
124.93
137.18
115.45
89.93
76.76
59.06
20.83
-54.48
26.07

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Shareholder's Funds
12,262.10
12,569.80
9,853.10
7,865.20
6,369.10
4,989.00
4,031.90
3,776.80
3,526.10
4,496.90
Share Capital
82.90
85.30
85.20
85.10
84.90
84.80
84.60
84.40
84.20
84.10
Total Reserves
12,098.80
12,393.90
9,677.40
7,698.60
6,215.30
4,849.10
3,906.80
3,657.40
3,403.00
4,377.60
Non-Current Liabilities
456.10
876.70
1,678.40
2,182.30
1,285.10
1,609.80
600.30
1,491.00
2,051.40
2,049.00
Secured Loans
59.70
74.70
77.50
94.70
80.20
26.10
24.40
26.90
38.60
64.20
Unsecured Loans
485.20
993.80
1,354.00
1,980.80
1,185.70
1,615.80
512.80
1,457.10
1,959.00
1,904.20
Long Term Provisions
84.20
95.20
77.90
56.30
51.40
33.30
28.80
0.00
0.00
0.00
Current Liabilities
8,419.90
6,347.10
6,821.30
5,790.40
5,658.80
4,591.40
4,208.50
2,024.80
1,711.20
1,150.80
Trade Payables
1,056.90
906.80
867.30
893.20
965.70
756.60
634.50
1,667.90
1,505.60
1,027.50
Other Current Liabilities
2,339.70
2,409.10
2,624.40
2,020.80
2,120.40
1,749.20
1,328.90
6.70
6.20
5.80
Short Term Borrowings
4,362.60
2,271.80
2,185.70
2,060.70
1,898.60
1,588.80
1,831.90
0.00
0.00
0.00
Short Term Provisions
660.70
759.40
1,143.90
815.70
674.10
496.80
413.20
350.20
199.40
117.50
Total Liabilities
21,138.10
19,793.60
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70
7,292.60
7,288.70
7,696.70
Net Block
6,930.70
6,563.00
5,377.00
4,640.80
4,050.60
3,411.70
3,385.50
2,352.20
2,927.00
3,912.50
Gross Block
15,932.40
15,019.70
12,573.60
11,917.60
10,089.40
8,842.30
7,975.10
6,446.80
6,502.70
5,487.80
Accumulated Depreciation
8,961.40
8,456.70
7,169.90
7,276.80
5,984.60
5,295.30
4,589.60
4,094.60
2,112.90
1,575.30
Non Current Assets
11,454.40
7,999.60
6,476.10
5,512.20
4,786.30
4,191.20
4,025.70
3,115.00
3,357.20
4,312.20
Capital Work in Progress
3,324.50
772.20
529.00
638.80
565.30
708.50
575.20
762.20
429.60
268.40
Non Current Investment
682.60
329.70
145.60
0.40
0.40
0.90
0.90
0.60
0.60
131.30
Long Term Loans & Adv.
482.10
290.40
418.10
232.20
149.10
70.10
64.10
0.00
0.00
0.00
Other Non Current Assets
34.50
44.30
6.40
0.00
20.90
0.00
0.00
0.00
0.00
0.00
Current Assets
9,683.70
11,794.00
11,876.70
10,325.70
8,526.70
6,999.00
4,815.00
4,177.60
3,931.50
3,384.50
Current Investments
1,427.10
3,503.40
2,102.20
1,066.40
196.60
207.00
0.00
357.40
51.70
350.80
Inventories
2,852.80
2,557.90
2,569.90
2,418.80
2,170.70
1,943.30
1,599.20
1,339.40
1,325.00
1,101.90
Sundry Debtors
3,798.60
4,125.00
4,101.20
3,325.30
3,180.40
2,536.80
1,761.10
1,159.90
1,440.60
652.20
Cash & Bank
386.50
492.10
1,872.40
2,300.60
2,017.10
1,606.10
575.10
660.00
562.30
744.70
Other Current Assets
1,218.70
393.10
226.20
170.40
961.90
705.80
879.60
660.90
551.90
534.90
Short Term Loans & Adv.
767.20
722.50
1,004.80
1,044.20
796.90
611.60
763.20
658.70
551.20
532.10
Net Current Assets
1,263.80
5,446.90
5,055.40
4,535.30
2,867.90
2,407.60
606.50
2,152.80
2,220.30
2,233.70
Total Assets
21,138.10
19,793.60
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70
7,292.60
7,288.70
7,696.70

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Cash From Operating Activity
2,144.40
3,262.60
2,523.50
1,969.70
1,377.90
1,612.60
755.40
1,315.00
599.10
512.80
PBT
1,553.70
2,858.80
2,899.60
2,646.30
2,164.70
1,804.40
1,182.80
618.30
-656.30
545.00
Adjustment
1,692.70
1,107.70
1,654.00
1,042.70
1,062.80
1,157.40
530.10
1,117.30
2,080.10
523.40
Changes in Working Capital
-525.00
-2.50
-1,483.70
-1,005.00
-1,294.40
-893.80
-658.70
-137.50
-545.60
-402.40
Cash after chg. in Working capital
2,721.40
3,964.00
3,069.90
2,684.00
1,933.10
2,068.00
1,054.20
1,598.10
878.20
666.00
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-577.00
-701.40
-546.40
-714.30
-555.20
-455.40
-298.80
-283.10
-279.10
-153.20
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,840.40
-2,039.40
-2,264.70
-1,694.10
-1,446.30
-1,888.40
-898.80
-710.20
-505.00
-810.40
Net Fixed Assets
-1,019.30
-1,892.20
-828.10
-819.60
-530.80
-554.40
-399.90
-602.60
-571.80
-424.90
Net Investments
1,974.20
-1,213.80
-1,055.80
-427.30
98.50
-15.70
93.10
-851.30
226.80
-1,100.39
Others
-2,795.30
1,066.60
-380.80
-447.20
-1,014.00
-1,318.30
-592.00
743.70
-160.00
714.89
Cash from Financing Activity
-369.20
-1,700.10
-433.20
-24.20
-156.80
389.10
44.50
-531.70
-265.10
-775.40
Net Cash Inflow / Outflow
-65.20
-476.90
-174.40
251.40
-225.20
113.30
-98.90
73.10
-171.00
-1,073.00
Opening Cash & Equivalents
492.10
539.50
862.40
520.40
736.20
573.00
660.00
562.30
744.70
1,861.00
Closing Cash & Equivalent
377.80
492.10
582.90
862.40
520.40
736.20
575.10
660.00
562.30
744.70

Financial Ratios

Consolidated /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Book Value (Rs.)
734.72
731.49
572.92
457.33
371.04
290.91
235.90
221.67
207.08
265.26
ROA
6.14%
11.05%
13.67%
13.47%
12.46%
12.99%
12.38%
4.82%
-12.24%
5.70%
ROE
10.20%
18.95%
26.63%
27.88%
27.18%
29.15%
25.83%
9.72%
-23.07%
10.41%
ROCE
9.77%
19.55%
22.69%
24.77%
24.79%
26.24%
20.84%
12.18%
-9.14%
10.02%
Fixed Asset Turnover
0.92
1.13
1.23
1.23
1.26
1.17
1.04
1.09
1.16
0.99
Receivable days
101.86
96.43
89.72
87.97
87.19
79.59
70.77
67.20
55.01
51.82
Inventory Days
69.56
60.11
60.27
62.06
62.74
65.60
71.20
68.85
63.79
66.85
Payable days
31.00
28.67
28.48
33.96
34.99
35.37
72.19
108.29
85.61
85.15
Cash Conversion Cycle
140.42
127.87
121.51
116.06
114.93
109.82
69.78
27.76
33.19
33.52
Total Debt/Equity
0.40
0.27
0.44
0.58
0.58
0.66
0.59
0.40
0.57
0.44
Interest Cover
25.51
35.61
27.80
21.89
22.58
16.81
37.62
17.06
-5.07
6.35

News Update:


  • Dr. Reddy’s launches Levetiracetam in Sodium Chloride Injection in US Market
    19th Jun 2018, 12:44 PM

    The company’s levetiracetam in Sodium Chloride Injection is available in strengths of 500 mg/100 mL (5 mg/mL), 1,000 mg/100 ml (10 mg/mL), and 1,500 mg/100 mL (15 mg/mL) single-dose infusion bags

    Read More
  • Dr. Reddy’s Lab receives approval for Buprenorphine and Naloxone Sublingual Film
    15th Jun 2018, 08:56 AM

    The product is being launched with an approved REMS Program

    Read More
  • Dr. Reddy’s expects to launch generic version of Copaxone in H1FY20
    8th Jun 2018, 12:43 PM

    Copaxone is a multi-billion dollar drug and a prescription medicine used for the treatment of people with relapsing forms of multiple sclerosis

    Read More
  • USFDA completes audit at Dr. Reddy’s API Srikakulam Plant
    4th Jun 2018, 10:34 AM

    USFDA has completed audit with no observations

    Read More
  • Dr Reddy’s Lab to launch over 15 products in US in FY19
    4th Jun 2018, 09:55 AM

    The drug major also remained optimistic for a double digit growth in the domestic market in the ongoing financial year

    Read More
  • Dr Reddy’s Laboratories reports 19% fall in Q4 consolidated net profit
    22nd May 2018, 16:33 PM

    Total consolidated income of the company decreased marginally by 0.93% at Rs 3598.80 crore for quarter under review

    Read More
  • Dr. Reddys Lab - Quarterly Results
    22nd May 2018, 13:10 PM

    Read More
  • Dr. Reddy’s receives EIR for API Mirfield Plant in UK
    24th Apr 2018, 11:57 AM

    Recently, the company has received the EIR from the USFDA for its API Cuernavaca plant in Mexico

    Read More
  • Dr. Reddy’s receives EIR for API Cuernavaca plant in Mexico
    10th Apr 2018, 11:40 AM

    In March 2018, USFDA had completed audit at company’s API Hyderabad plant I at Jinnaram Mandal, Medak District, Telangana

    Read More
  • Dr. Reddy’s, Promius Pharma file NDA for migraine candidate with USFDA
    3rd Apr 2018, 11:12 AM

    The filing of DFN-02 NDA represents the company’s continuing commitment to bring innovative solutions in migraine treatment

    Read More
  • Dr. Reddy’s launches Palonosetron Hydrochloride Injection in US Market
    26th Mar 2018, 11:01 AM

    Dr. Reddy’s Palonosetron Hydrochloride Injection is available in strength of 0.25 mg/5 mL (free base) in a single-dose vial packaged in a carton containing one vial

    Read More
  • USFDA completes audit at Dr. Reddy’s API Hyderabad plant
    16th Mar 2018, 15:26 PM

    USFDA has issued a Form 483 with four observations

    Read More
  • Dr. Reddy's Laboratories launches Levocetirizine Dihydrochloride Tablets
    16th Mar 2018, 11:39 AM

    The Xyzal Allergy 24HR Tablets brand had US sales of around $71 million for the most recent 12 month ending January 2018 according to IRI

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.